AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04429529 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TY027
Description: TY027 Injection, (100 mg/5 mL/Vial), SARS-CoV-2 Monoclonal Antibody (mAb)
Study NCT04429529 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: Placebo
Study NCT02988869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium/Formoterol
Description: Tiotropium/Formoterol 18/12 mcg Inhalation Powder (1 puff) once daily via Discair®
Study NCT02988869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler
Study NCT00488592 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WT1:126-134
Description: Subjects were given 6 doses of PR1:169-177 in Montanide adjuvant and 6 doses of WT1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
Study NCT00488592 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PR1:169-177 Peptide
Description: Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
Study NCT00488592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF (Sargramostim)
Description: Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
Study NCT00488592 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Montanide adjuvant
Description: Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
Study NCT01359592 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Study NCT01359592 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT01359592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Study NCT01359592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Study NCT02988869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Formoterol 12 mcg Inhalation Powder (1 puff) twice daily via Aerolizer
Study NCT01359592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Study NCT01359592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Study NCT01359592 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: R-CHOP regimen
Study NCT01359592 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Study NCT01359592 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT01359592 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Study NCT01359592 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: selective external radiation therapy
Study NCT01359592 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan
Study NCT00674401 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency catheter ablation
Description: * In case of Paroxysmal AF, patients will be randomized into one of 2 in the study:~  1. Empirical pulmonary vein antrum circumferential isolation, or~ 2. High frequency sites ablation in the LA~* In case of Persistent AF, patients will be randomized into one of 2 in the study:~  1. Empirical circumferential PV antrum isolation w/out roof line, or~ 2. A combined approach involving PV antrum isolation w/out roof line and high frequency sites ablation.
Study NCT01983319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active anodal transcranial Direct Current Stimulation (tDCS)
Description: Anodal transcranial Direct Current Stimulation 1.5 mA in 30 minutes with CIMT
Study NCT04185571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEPA
Study NCT02711436 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography Scan
Study NCT02711436 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fast Magnetic Resonance Imaging
Study NCT01983319 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham transcranial Direct Current Stimulation
Description: sham transcranial Direct Current Stimulation 30 min with CIMT
Study NCT01983319 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constraint Induced Movement Therapy (CIMT)
Description: 2 weeks of CIMT
Study NCT01794247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Study NCT05456048 — intervention group
Intervention type: DRUG
Intervention: VEN+HMA regimen
Description: VEN was prescribed as 100mg day 1, 200mg day 2, 400mg day 3-28; AZA was used at the dose of 75 mg/m2, day 1-7 or DEC 20mg/m2 day 1-5. The dose of VEN was reduced to 100mg/d if co-administered with posaconazole or voriconazole.
Study NCT01779414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STAT-ED Intervention
Description: Participants in this group will receive a motivational interview conducted by a study trained social worker, where the social worker and the family will discuss the participants issues, thoughts and feelings about receiving treatment, barriers to treatment and methods of overcoming those barriers. The study trained social worker will also make a referral for a mental health follow-up for the patient.
Study NCT02944890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug Eluting Balloon Catheters(RESTORE DEB）
Study NCT02944890 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug Eluting Balloon Catheters(SeQuent® Please）
Study NCT00968409 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: PET
Description: PET imaging following injection of F18-FFNP to image hormone receptor status in patients with newly diagnosed breast cancer
Study NCT00968409 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Laboratory Testing
Description: Blood and urine samples for standard laboratory testing and radioactive counts will be obtained during the imaging sessions. Testing will include: urinalysis, complete blood count, comprehensive metabolic panel, and progesterone levels
Study NCT00968409 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Safety Testing
Description: ECG tracings and vital signs (blood pressure, heart rate, body temperature and respiration rate) are obtained at several time points before, during and after the imaging sessions.
Study NCT00968409 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: F18-FFNP
Description: injection of F18-FFNP
Study NCT04038073 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Antistreptolysin O Test
Description: Test to evaluate of any histories of streptococcal infections
Study NCT04038073 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Anti-Deoxyribonuclease B
Description: Test to evaluate of any histories of streptococcal infections
Study NCT04038073 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: TLR, MyD88, IRAK-4 polymorphism
Description: Test to evaluate of the frequency and types of genetic alterations of innate immunity
Study NCT04038073 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Anti-Basal Ganglia Antibody
Description: Test to evaluate the autoimmune component
Study NCT01959529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected once daily subcutaneously (s.c., under the skin)
Study NCT01959529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Injected once daily subcutaneously (s.c., under the skin)
Study NCT01555060 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferrous gluconate
Description: daily capsule of ferrous gluconate containing 38 mg of elemental iron
Study NCT01510093 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Insulin Aspart 100 IE/ml
Description: 1.5 IE/hour/subject/visit. Each vist takes 10 hours
Study NCT00329030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Autologous transplantation using rituxan/BEAM
Description: Rituxan 375 mg/m2 (Day -19 and Day -12); BCNU 300 mg/m2 (Day -6); Etoposide (VP-16) 100 mg/m2 twice a day (Days -5 to -2); Cytarabine 100 mg/m2 twice a day (Days -5 to -2); Melphalan 140 mg/m2 (Day -1); Followed by autologous transplantation
Study NCT00329030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous transplantation using Bexxar/BEAM
Description: Bexxar dosimetric dose 5 mCi (Day -19); Bexxar therapy dose 75 cGy TBD (Day -12); BCNU 300 mg/m2 (Day -6); Etoposide (VP-16) 100 mg/m2 twice a day (Days -5 to -2); Cytarabine 100 mg/m2 twice a day (Days -5 to -2); Melphalan 140 mg/m2 (Day -1); Followed by autologous transplantation
Study NCT01544673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linezolid
Description: 600 mg oral tablet twice daily for 4.5 days
Study NCT01544673 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg oral placebo twice daily for 4.5 days
Study NCT02791464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation program
Description: a mental technique using a mantra or 'soothing sound' that refines the thought process enabling the mind to 'transcend' its own thinking process and experience a state of pure consciousness. Subjects practice this technique twice a day for 20 minutes sitting in chair with eyes closed.
Study NCT04252014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hookah tobacco messages
Description: Messages communicating the risks of hookah tobacco use in 4 thematic areas: health harms, addictiveness, social use, flavorings.
Study NCT00216281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clozapine augmented with atomoxetine up to 40 mg or placebo
Study NCT00216281 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clozapine augmented with atomoxetine up to 40 mg or placebo
Study NCT03401320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole ISM
Description: 2.5 mg Femara + single IM injection of 50-400 mg Letrozole ISM
Study NCT03064828 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CT colonoscopy(normal dose)
Description: Perform CT colonoscopy with full bowel preparation and inflated colon,CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kVp, 100-200mA
Study NCT03064828 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT colonoscopy (low dose)
Description: Perform CT colonoscopy with full bowel preparation and inflated colon,CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kVp, 20-100mA
Study NCT03156829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Splint
Description: Custom made splint
Study NCT03156829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone
Description: Corticosteroid Injection Brand name of the drug: Celestone Soluspan Dosage: 6 mg/ml
Study NCT03156829 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Splint + Cortico-steroid injection
Description: Splint + Cortico-steroid injection given in combination
Study NCT00875914 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RF-ablation
Description: 4mm-tip catheter manually guided vs magneticallly navigated
Study NCT02668666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib 125 mg will be administered orally once daily on days D1-D21 of each 28-day cycle. Subjects will not take palbociclib on D22-D28.
Study NCT01238510 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stent technique: Routine fKBT
Description: Mandatory use of fKBT irrespective of SB flow after stenting for non-left main bifurcation. Additional stenting for SB is recommended if residual stenosis (>50% in visual) or TIMI flow grade (\<TIMI 3) was seen at SB after fKBT.~Stent type: Everolimus-eluting stent only
Study NCT04447794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step Away Chatbot
Description: The Step Away chatbot utilizes AI technology to provide mobile, web-based, person-centered, behavioral-based interventions and timely support for individuals seeking to reduce their alcohol use. Participants interact with the chatbot through interactive text.~The Step Away chatbot is informed by the following theoretical constructs: (1) motivational enhancement; (2) relapse prevention; and (3) community reinforcement. It uses the Relapse Prevention (RP) model, which is informed by cognitive behavioral theory and has evolved to reflect the dynamic, non-linear relationships between contextual triggers and coping, as mediated by motivation, mood, and self-efficacy. It proactively encourages the user to identify and include supportive others in treatment; to identify and plan non-drinking, recreational activities; and to develop other non-drinking lifestyle skills and strategies.
Study NCT04447794 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Step Away App
Description: The Step Away app is a smartphone-based mobile intervention system.~It is informed by three theoretical constructs that are considered the most important active ingredients for person-centered, behavioral-based intervention and treatment in addictions: (1) motivational enhancement; (2) relapse prevention; and (3) community reinforcement. Step Away uses the Relapse Prevention (RP) model, which is informed by cognitive behavioral theory and has evolved to reflect the dynamic, non-linear relationships between contextual triggers and coping, as mediated by motivation, mood, and self-efficacy. Step Away proactively encourages the user to identify and include supportive others in treatment; to identify and plan non-drinking, recreational activities; and to develop other non-drinking lifestyle skills and strategies.
Study NCT01601041 — intervention group
Intervention type: OTHER
Intervention: sonographic assessment of residual urine, urine culture
Description: residual urinary volume assessed by ultrasound after bladder catheterization urinary cultures taken before and after prostate massage
Study NCT01485653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine
Description: Group 1) 20mL 1.5% mepivacaine, one dose Group 2) 30mL 1.5% mepivacaine, one dose
Study NCT03789955 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluoroscopic-guided TEB
Description: When performing a fluoroscopic-guided thoracic epidural block (TEB), an 18-gauge Tuohy needle will be used for interlaminar epidural access. If the epidural space was accessed under fluoroscopic guidance and using the loss of resistance technique with air. All procedures will be performed with a paramedian approach under the true AP and lateral view at first, If the interlaminar space is not visible, the CLO view will be used. If the needle is deemed to be in the epidural space when the loss occurred, six fluoroscopic views will be obtained: true AP, CLO at 40 degrees, 50 degrees, 60 degrees, CLO measured, and lateral. The CLO measured angle will be determined by measuring the angle between the superior lamina and spinous process on the midsagittal plane on thoracic MRI or CT.
Study NCT03762668 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Modified delefilcon A contact lenses
Description: Spherical soft daily disposable contact lens
Study NCT03762668 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A contact lenses
Description: Spherical soft daily disposable contact lens
Study NCT03712306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary advice
Description: Dietary advice to increase protein intake to at least 1.2 g/kg adjusted body weight/d
Study NCT03712306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary advice and advice on timing
Description: Dietary advice to increase protein intake to at least 1.2 g/kg adjusted body weight/d plus advice on consuming protein in close proximity of usual physical activity
Study NCT04383730 — intervention group
Intervention type: DRUG
Intervention: Intravenous sedation
Description: Patients will be included retrospectively in the study by local investigators at each participating center. As this is a non-interventional study, sedation practices will be those currently used as standard practices in participating centers, including both intravenous and inhaled sedation practices
Study NCT04383730 — intervention group
Intervention type: DRUG
Intervention: Inhaled sedation
Description: Patients will be included retrospectively in the study by local investigators at each participating center. As this is a non-interventional study, sedation practices will be those currently used as standard practices in participating centers, including both intravenous and inhaled sedation practices
Study NCT01271517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH insulin
Description: Treatment twice daily with Insulatard plus Novorapid at meals. Doses adjusted according to bloodsugar
Study NCT01271517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Description: Treatment once daily with Lantus plus Novorapid at meals. Doses adjusted according to bloodsugars
Study NCT01271517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Detemir
Description: Treatment twice daily with Levemir plus Novorapid at meals. Doses adjusted according to bloodsugars
Study NCT03814265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laughter yoga
Description: 440/5000 Laughter yoga; It is an exercise program that combines breathing techniques with unconditional laughter. During the sessions, laughter is simulated by hand clapping and warm-up exercises and by eye contact with other members in the group and by playing childish games with group members. Most of the time this simulation turns into genuine and contagious laughter. Laughter yoga is based on the argument that the brain cannot distinguish between real and unreal laugh.
Study NCT03737591 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Next-generation sequencing (NGS)
Description: NGS test for colorectal tumor-specific plasma ctDNA methylation markers prior to endoscopy
Study NCT01324453 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post Conditioning + Primary PCI
Description: Four, 30-second PTCA balloon occlusions followed by 30-seconds of reperfusion over a total of 4 minutes, in addition to Percutaneous Coronary Intervention as clinically indicated.
Study NCT01324453 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Primary PCI
Description: Routine Percutaneous Coronary Intervention as clinically indicated.
Study NCT01794247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Study NCT01794247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Study NCT01794247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Study NCT02830035 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Real-time Ultrasound-guided
Description: Real-time ultrasound guided paramedian spinal anesthesia
Study NCT02830035 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomical Landmark Technique
Description: Conventional anatomical landmark technique for paramedian spinal anesthesia
Study NCT02292992 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Pillow CPAP
Description: Nasal Pillow CPAP in extubated patients
Study NCT04368455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Immersive Communication Training on Recommending Immunizations (VICTORI)
Description: An intervention that includes a self-directed app based curriculum and virtual reality simulations, designed to increase the strength and consistency of HPV vaccine recommendations among clinicians.
Study NCT04368455 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HPV Same Way Same Day App
Description: An intervention that includes a self-directed app based curriculum